LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 77 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $157,000 | -29.9% | 133,051 | -16.2% | 0.00% | – |
Q2 2023 | $223,867 | -67.8% | 158,771 | -65.7% | 0.00% | – |
Q1 2023 | $694,326 | +24.4% | 462,884 | -3.0% | 0.00% | – |
Q4 2022 | $558,294 | +262.5% | 477,174 | +250.9% | 0.00% | – |
Q3 2022 | $154,000 | +1825.0% | 135,981 | +2657.7% | 0.00% | – |
Q2 2022 | $8,000 | -42.9% | 4,931 | -45.4% | 0.00% | – |
Q1 2022 | $14,000 | -83.9% | 9,037 | -74.6% | 0.00% | – |
Q4 2021 | $87,000 | -74.9% | 35,607 | -74.2% | 0.00% | – |
Q3 2021 | $347,000 | +951.5% | 137,858 | +1082.0% | 0.00% | – |
Q2 2021 | $33,000 | +73.7% | 11,663 | +43.4% | 0.00% | – |
Q1 2021 | $19,000 | +90.0% | 8,136 | +38.1% | 0.00% | – |
Q4 2020 | $10,000 | +66.7% | 5,891 | 0.0% | 0.00% | – |
Q3 2020 | $6,000 | +20.0% | 5,891 | 0.0% | 0.00% | – |
Q2 2020 | $5,000 | -83.9% | 5,891 | -84.1% | 0.00% | – |
Q1 2020 | $31,000 | +3.3% | 37,110 | +8.6% | 0.00% | – |
Q4 2019 | $30,000 | +100.0% | 34,175 | +119.1% | 0.00% | – |
Q3 2019 | $15,000 | – | 15,598 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Defender Capital, LLC. | 4,735,990 | $8,335,000 | 3.63% |
BROADWOOD CAPITAL INC | 34,005,379 | $59,849,000 | 3.55% |
Prescott General Partners LLC | 1,851,851 | $3,259,000 | 0.14% |
Strategic Wealth Investment Group, LLC | 66,917 | $118,000 | 0.07% |
Laidlaw Wealth Management LLC | 170,658 | $300,000 | 0.06% |
Humankind Investments LLC | 26,737 | $47,000 | 0.05% |
DAFNA Capital Management LLC | 80,000 | $141,000 | 0.04% |
Beirne Wealth Consulting Services, LLC | 45,000 | $79,000 | 0.04% |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 680,839 | $1,198,000 | 0.02% |
Allegheny Financial Group LTD | 20,000 | $35,000 | 0.02% |